 "Divi's Lab sinks 13%, hits 29-mth low as Q3 profit falls more than expected")
Shares of Divis Laboratories tanked 13 per cent to hit a 29-month low of Rs 2,830 on the BSE in Friday’s intra-day trade as the company posted weak results for the December quarter (Q3FY23) disappointing investors.
The stock of the pharmaceutical company was quoting at its lowest level since August 2020. In comparison, the S&P BSE Sensex was up 1 per cent at 60,543 at 02:12 pm.
In Q3FY23, Divis Labs reported a 66 per cent year-on-year (YoY) decline in its consolidated net profit at Rs 306.80 crore, on higher than expected fall in revenue. The company’s consolidated revenue came 31.5 per cent lower to Rs 1,707.68 crore as against analyst’s expectation of around Rs 1,888 crore. ICICI Securities had expected the net profit to de-grow 40 per cent YoY to Rs 541 crore.
The earnings before interest, depreciation, tax and amortization (EBIDTA) was down 63 per cent YoY to Rs 408 crore from Rs 1,097 crore in the year-ago period. EBITDA margins contracted sharply to 23.9 per cent from 44 per cent in Q3FY22.
Material consumption for this quarter came to be about 43 per cent of sales revenue due to change in product mix, the company said. The group is engaged in the manufacturing of active pharmaceutical ingredients (API), intermediates, and nutraceutical ingredient.
The stock of the pharmaceutical company was quoting at its lowest level since August 2020. In comparison, the S&P BSE Sensex was up 1 per cent at 60,543 at 02:12 pm.
In Q3FY23, Divis Labs reported a 66 per cent year-on-year (YoY) decline in its consolidated net profit at Rs 306.80 crore, on higher than expected fall in revenue. The company’s consolidated revenue came 31.5 per cent lower to Rs 1,707.68 crore as against analyst’s expectation of around Rs 1,888 crore. ICICI Securities had expected the net profit to de-grow 40 per cent YoY to Rs 541 crore.
The earnings before interest, depreciation, tax and amortization (EBIDTA) was down 63 per cent YoY to Rs 408 crore from Rs 1,097 crore in the year-ago period. EBITDA margins contracted sharply to 23.9 per cent from 44 per cent in Q3FY22.
Material consumption for this quarter came to be about 43 per cent of sales revenue due to change in product mix, the company said. The group is engaged in the manufacturing of active pharmaceutical ingredients (API), intermediates, and nutraceutical ingredient.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →Subscribe to Business Standard digital and get complimentary access to The New York Times
Quarterly Starter
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
Save 46%
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%